Malaysian Genomics Resource Centre Bhd. · MYX:MGRC
Malaysian Genomics Resource Centre Bhd — Shareholder Meeting (December 2014)
9 slides from Malaysian Genomics Resource Centre Bhd's shareholder meeting presentation, Dec 10, 2014
Slide 1: An Update, 10.12.14
Text An Update, 10.12.14 Malaysian Genomics Resource Centre Berhad
Slide 2: Our Journey So Far
Our Journey So Far Growth Focus on marketing. Established credentials and Transformation reputation. Tap into global industry: Reinvested in R&D to create new consumer segment - ‣ Outsource Contract Analytics. Journey Screening Services Main stream of revenue ‣ More Contract Analytics from Contract
Slide 3: Malaysian Genomics Today
Malaysian Genomics Today Proprietary Analytical Pipelines Genetic & Genomic Expertise Analytical Services Screening Services Pathology Lab Diagnostic Services Plant Human Science Health Local, foreign institutions Local, foreign hospitals, clinics, doctors, and allied health specialists © Copyright
Slide 4: Broadening Earnings Base
Broadening Earnings Base Listing Transformation Direction FY2010 FY2014 FY2017 15% 5% 5% 20% 100% 8% 67% 100% 80% Analytical Services Analytical Services Analytical Services Pathology Lab Pathology Lab Screening Services Screening Services Diagnostic Services © Copyright 2014. Malaysian Genomics Res
Slide 5: Growth Opportunities: Analytical Services
Growth Opportunities: Analytical Services Global Market 1,2 CAGR 21% (today – 2018), revenue US$8 – 12 billion 2018 est. Increase in outsourcing to Asia from US and EU. Key Drivers falling more greater demand sequencing accessible for sequencing costs sequencing and analysis mean means means more gr
Slide 6: Growth Opportunities: Analytical Services
Growth Opportunities: Analytical Services For Malaysian Genomics: We increased Analytical Services in healthcare (e.g. FELDA Wellness Project) and in agriculture. We started marketing beyond Malaysia for regional work. We have seen positive transitions from Sales Pipeline to Order Book. 25.0 Order B
Slide 7: Growth Opportunities: Pathology Lab
Growth Opportunities: Pathology Lab Current Situation 2014 RM428m (est.) a) Clinipath; 6% has 11 branch labs serving 2,000 doctors; and operates in 7 medical centres. b) Clinipath holds 6% share of Malaysia’s RM428 million 94% private sector pathology market (2014 est.) Expansion Plan 2019 RM754m (e
Slide 8: Growth Opportunities: Diagnostic Services
Growth Opportunities: Diagnostic Services Current Situation a) Used for 70% of healthcare decisions made by doctors. b) Global market revenue US$80 billion (2020 est., Forbes). c) Fastest growing segment is molecular diagnostics. Expansion Plan a) Partner program with leading US and EU labs to bring
Slide 9: Thank you
Text Thank you Malaysian Genomics Resource Centre Berhad
Malaysian Genomics Resource Centre Berhad — Shareholder Meeting (December 2014) on 6ix